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Abstract: The TAM (Tyro3, Axl, MerTK) subfamily of receptor tyrosine kinases (RTKs) and their
ligands, Gas6 and protein S (ProS1), are implicated in tumorigenesis and chemoresistance in various
cancers. The β-galactoside binding protein galectin-3 (Gal-3), which is also implicated in oncogenesis,
has previously been shown to be a ligand for MerTK. However, the selectivity of Gal-3 for the other
TAM receptors, and its TAM-mediated signalling and functional properties in cancer cells, remain to
be explored. The present study was aimed at determining these, including through direct comparison
of Gal-3 with the two canonical TAM ligands. Exogenous Gal-3 rapidly stimulated Tyro3 receptor
phosphorylation to the same extent as the Tyro3 ligand ProS1, but not Axl, in the cultured human
cancer cell lines SCC-25 (express both Tyro3 and Axl) and MGH-U3 (express Tyro3 only). Gal-3 also
activated intracellular Erk and Akt kinases in both cell lines and furthermore protected cells from acute
apoptosis induced by staurosporine but not from serum-starvation induced apoptosis. In addition,
Gal-3 significantly stimulated cancer cell migration rate in the presence of the Axl blocker BGB324.
Therefore, these results have shown Gal-3 to be a novel agonist for Tyro3 RTK, activating a Tyro3-Erk
signalling axis, as well as Akt signalling, in cancer cells that promotes cell survival, cell cycle progression
and cell migration. These data therefore reveal a novel mechanism of Tyro3 RTK activation through
the action of Gal-3 that contrasts with those of the known TAM ligands Gas6 and ProS1.
Keywords: Galectin-3; Tyro3; Axl; MerTK; Gas6; protein S; receptor tyrosine kinase; cancer; ligand;
signal transduction
1. Introduction
Tyro3, Axl and MerTK (TAM) are members of a subfamily of receptor tyrosine kinases (RTKs),
characterised by homology in terms of gene origins and genomic organisation, amino acid sequence
identity and homologous protein domain compositions [1,2]. Furthermore, the TAMs share in common
two homologous ligands, namely the vitamin K-dependent proteins Gas6 and protein S (ProS1) [3].
Many studies to date have elucidated the ligand-mediated signalling pathways and functional effects
upon activation of the TAM receptors. This includes cancer studies, where each of the TAMs has been
shown to be involved in the pathobiology of different tumour types, through aberrant activation in
either ligand-dependent or -independent manners [4,5]. The canonical TAM ligands have different
affinities for each TAM receptor, Gas6 being able to activate all three TAMs whereas ProS1 activates
only Tyro3 and MerTK [3,4]. Nevertheless, both ligands are thought to interact with the receptors
through similar contact sites within their homologous domains.
Much remains to be discovered about Tyro3 RTK in terms of its ligand sensitivity, activation
mechanisms and downstream signalling pathways. Recently, we reported that ProS1 is the preferred
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ligand for Tyro3 receptor in human cancer cells that express multiple TAMs, and identified two discrete
signalling axes, ProS1-Tyro3-Erk and Gas6-Axl-Akt, that exist side by side in these cells, mediating
proliferative and survival signalling, respectively [6]. However, in addition to the two canonical TAM
ligands, evidence has recently been emerging for new non-canonical ligands for the TAM receptors,
interacting through different protein–protein interfaces. One of these novel ligands is galectin-3
(Gal-3), for which MerTK was identified as one of several glycan-conjugated novel binding partners [7].
Gal-3 activation of MerTK was shown to stimulate the phagocytic activity of macrophages [7,8].
However, the biophysical nature of the Gal-3–MerTK interaction was not determined, nor is it known
whether Gal-3 could also be a ligand for the other TAM receptors.
As with the other members of the evolutionarily conserved galectin class of proteins,
Gal-3 possesses a specific carbohydrate-recognition domain (CRD) through which the protein binds
to glycoconjugates containing β-galactosides [9]. However, a unique feature of Gal-3 is its chimeric
composition of three structural domains: an N-terminal domain composed of a short leader sequence,
a collagen-like internal repeating domain rich in glycine, tyrosine and proline, and the C-terminal
CRD. Gal-3 is expressed by many types of human cells including epithelial and immune cells, and also
shows a wide sub-cellular distribution [10]. This wide distribution of Gal-3 and its interactions with
multiple protein-linked glycans underlie its reported involvement in various cellular processes such
as cell differentiation, cell growth, cell apoptosis, cell adhesion, cell cycle regulation, cell migration,
immune activation, angiogenesis and chemoattraction [11].
Aside from its functions in the normal state, a pathological role for Gal-3 in contributing to
cancer progression has been increasingly uncovered. Elevated levels of Gal-3 observed in leukaemia,
lymphomas, breast and thyroid cancer are prognostic for poor patient survival [10]. Additionally,
overexpression of Gal-3 has been also reported in multiple cancers including melanoma, head and
neck cancer, colorectal, lung, breast and prostate, and Gal-3 was shown to promote tumour growth and
protect cancer cells from apoptosis [12]. Amongst its cancer-related molecular interactions, Gal-3 has
been shown to be a ligand for the RTKs epidermal growth factor receptor (EGFR) and vascular
endothelial growth factor receptor-2 (VEGFR-2), activating signalling pathways for cell proliferation
and angiogenesis respectively [13].
In the present study, we have demonstrated that Gal-3 is a novel functional agonist for Tyro3 RTK
in human cancer cells and have compared it directly against both well-established TAM ligands Gas6
and ProS1. We have shown that Gal-3 selectively activates Tyro3 but not Axl, and in a distinct manner to
the other ligands, uncovering versatility to Tyro3 agonist responsiveness and the intracellular signalling
pathways it couples to. Furthermore, we show that Gal-3 promoted cell survival, and stimulated
anti-apoptotic gene expression as well as cancer cell migration.
2. Materials and Methods
2.1. Cell Culture
The human head and neck squamous cell carcinoma cell line SCC-25 (head and neck squamous
cell carcinoma; ATCC), expressing both Tyro3 and Axl RTKs, and the human bladder cancer cell line
MGH-U3 (gift from Prof. Margaret Knowles, University of Leeds), expressing Tyro3 as sole TAM
receptor, were maintained in complete culture medium (DMEM + 10% FBS) at 37 ◦C in a humidified
incubator with 5% CO2 as previously described [6].
2.2. Cell Treatments
Cells were first serum starved for 24 h, then treated with recombinant human Gas6 developed
in-house [14], recombinant human ProS1 (7.5 nM) (Cambridge Protein Works, Cambridge, UK) [6]
or recombinant human galectin-3 (Gal-3; 0.2 µM) (Cell Guidance Systems, Cambridge, UK). In some
experiments, staurosporine (Sigma Aldrich, Gillingham, UK; 0.1 µM) was added to cells to trigger
apoptosis over a 20 h incubation period, in the presence or absence of test ligands.
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2.3. RNA Extraction and Quantitative Real-Time Polymerase Chain Reaction
Total RNA was isolated from untreated and treated (24-h incubation) cells using the RNeasy Mini
Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. In the last step, RNA was
eluted with RNAse-free sterile water (40 µL). cDNA was synthesised using the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, CA, USA) with 1 µg of RNA template in a 20µl reaction.
Real-time PCR was performed for each gene using pre-designed assays containing specific primers and
fluorescent hydrolysis probes (Integrated DNA Technologies, Belgium) (Table S1). The experiments
were performed using the FastStart Essential DNA Probes Master reaction mix (Roche, Burgess Hill,
UK) and run on a LightCycler® 96 System machine (Roche). The amplification procedure entailed
45 cycles of 95◦C for 10 s followed by 60 ◦C for 30 s. For each reaction, GAPDH was utilised as the
endogenous control gene. The average mRNA fold change in drug-treated samples was normalised
against untreated samples using the 2-∆∆CT method [14]. Three independent experiments were carried
out and all samples were run in triplicates in each experiment.
2.4. SDS-PAGE and Western Blotting
Cells were lysed in ice-cold RIPA buffer (150 mM NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0) supplemented with a cocktail of protease and phosphatase
inhibitors. Cell lysates were subjected to sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE). The separated proteins were transferred by a wet transfer method onto an activated
polyvinylidene fluoride membrane (Millipore, Nottingham, UK). Membranes were incubated for 1 h
at room temperature in blocking buffer, which was either Tris-buffered saline-Tween 0.1% (TBS-T;
Fisher Scientific, Loughborough, UK) containing 3% non-fat dry milk, or otherwise containing 3%
bovine serum albumin (BSA; Fisher Scientific) if probing for phosphorylated proteins. Western blotting
was performed on extracts using specific antibodies to detect activated, phosphorylated, forms of
Tyro3, Axl, Erk and Akt, as well as GAPDH as a protein loading control, as previously described [6].
The primary antibodies (and dilutions) used were: phospho-Tyro3 (rabbit polyclonal; 1:1000; Sigma)
phospho-Axl (rabbit polyclonal; 1:500; R&D systems, Minneapolis, MN, USA), phospho-Erk (mouse
monoclonal 1:1000; Cell Signaling Technology (CST), London, UK), phospho-Akt 1/2/3, phospho-Tyro3
(rabbit polyclonal; 1:1000; Sigma),β-actin (rabbit polyclonal; 1:5000; CST), Gal-3 (goat polyclonal; 1:1000;
R&D systems) and GAPDH (mouse monoclonal 1:1000; Santa Cruz, Dallas, TX, USA). Secondary
antibodies used were donkey anti-rabbit HRP (1:2000; Dako, Denmark), anti-goat HRP (1:5000;
Dako) and anti-mouse HRP (1:5000; Promega, Southampton, UK). To produce blots of the best quality,
blots were probed for total protein loading through probing for GAPDH, as we have done previously [6],
after having first ensured that total Tyro3/Erk/Akt protein levels do not change over the stimulation
period that we used in our experiments (Figures S1 and S6). The software ImageJ was used for
densitometric quantification of Western blot band intensities [15].
2.5. Cell Survival/Growth Assay
The effects of various treatments on cell survival/growth were determined by measuring
the reduction in [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H
tetrazolium] (MTS) compound (CellTiter 96 Aqueous, Promega) in the presence of phenazine
methosulphate (PMS) (Sigma). Cells were seeded in 96-well plates and incubated overnight, prior to
indicated treatments for various periods, after which MTS (0.4 µM) was added to cells together
with PMS (0.3 nM) and incubated further for 2 h, and absorbance was measured at 490 nm using a
spectrophotometric microplate reader (Synergy; BioTek, Potton, UK).
2.6. Flow Cytometry
Cells in plates were treated with exogenous proteins Gas6, ProS1 and Gal-3 for 2 h before staurosporine
(0.1 µM) was added to trigger apoptosis for a further 20 h. Following treatments, the cells were washed
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with PBS, trypsinised, collected by centrifugation and re-suspended in 500 µL of binding buffer. The cells
were double stained by adding 5 µL of Annexin V-FITC and 5 µL of propidium iodide and incubated
at room temperature for 10 min in the dark. Cells were then analysed by flow cytometry using BD
FACSCalibur™ (BD Biosciences, New Jersey, NJ, USA) according to a standard procedure (PI: 493 nm
(excitation)/636 nm (emission), Annexin V-FITC: 488 nm (excitation)/530 nm (emission)), and the generated
data were analysed using FlowJo-V10 software (BD Life Sciences, Franklin Lakes, NJ, USA).
2.7. Scratch Wound Assay
Linear cell migration along a surface was measured by scratch wound assay. A linear scratch was
made in a confluent cell monolayer with the end of a 200 µL pipette tip. Images of marked wells were
captured at time 0 (when the scratch was made), then again after 21 h, using an inverted live imaging
microscope (etaluma 488; Etaluma, San Diego, CA, USA). Image analysis following the experiment
was performed using ImageJ software [16], and cell migration rates (area change/hour) were calculated.
2.8. Statistical Analysis
All data are expressed as the mean ± SEM obtained from a minimum of three independent
experiments unless otherwise stated in the figure legend. Quantitative data were analysed by Analysis
of Variance (ANOVA) with post-hoc Tukey test for multiple comparisons with one control group or
multiple time points/treatments. Statistical analyses and graphical representations were produced
using Prism software v.8.2.1 (GraphPad Software Inc, San Diego, CA, USA). The level of statistical
significance is indicated in the figures and accompanying legends. Differences between groups were
considered statistically significant based on the following criteria: * p < 0.05, ** p < 0.01, *** p < 0.001
and **** p < 0.0001.
3. Results
3.1. Galectin-3 is Expressed in a Range of Human Cancer Cell Lines
We first analysed the expression of Gal-3 in a range of human cancer cell lines at mRNA and
protein levels. Gal-3 was widely expressed across the cell line panel, with the expression level ranging
from high in melanoma, bladder and head and neck cancer cells, to low in glioma cells (Figure 1).
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separate experiments). (B) Western blot screen of Gal-3 protein expression in ten human cancer cell 
lines. Equal amounts of total protein were loaded and blot probed with anti-Gal-3 antibody. 
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selected for comparative experiments according to their TAM receptor expression profiles: the head 
and neck cancer cell line SCC-25, which expresses both Axl and Tyro3, and the bladder cancer cell 
line MGH-U3, which expresses Tyro3 only. Time-course and dose response experiments with 
exogenous recombinant human Gal-3 protein were performed, and the phosphorylation levels of 
both Tyro3 and Axl in SCC-25 cells, and of Tyro3 in MGH-U3 cells, were determined by Western 
blotting. In both cell lines, Gal-3 rapidly stimulated phosphorylation of Tyro3, peaking at 10 min 
and decreasing thereafter (Figure 2). Significant Tyro3 activation was observed by Gal-3 from 0.1 
μM concentration, with maximal activation occurring at 0.2 μM in both cell lines. As we used 
GAPDH as a loading control in the blots, we verified that the levels of total kinases did not change 
over the time periods of the experiments (Figure S1). In contrast to its effect on Tyro3, Gal-3 had no 
effect on Axl phosphorylation levels in SCC-25 cells over the 15 min time period of study (Figure 
S2). 
Figure 1. Expression of Gal-3 in human cancer cell lines. (A) Quantitative RT-PCR analysis of mRNA
expression of Axl, MerTK, Tyro3, Gas6 and ProS1 in five human cancer cell lines. Bars are the mean
± SEM relative gene xpression normalised against the housekeeping ge e GAPDH (n = 3 separate
experiments). (B) Western blot screen of Gal-3 protein expression in ten human cancer cell lines. Equal
amounts of total protein were loaded and blot probed with anti-Gal-3 antibody.
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3.2. Galectin-3 Activates Tyro3 But Not Axl
In order to investigate Gal-3 as a potential TAM ligand, two human cancer cell lines were selected
for comparative experiments according to their TAM receptor expression profiles: the head and
neck cancer cell line SCC-25, which expresses both Axl and Tyro3, and the bladder cancer cell line
MGH-U3, which expresses Tyro3 only. Time-course and dose response experiments with exogenous
recombinant human Gal-3 protein were performed, and the phosphorylation levels of both Tyro3 and
Axl in SCC-25 cells, and of Tyro3 in MGH-U3 cells, were determined by Western blotting. In both cell
lines, Gal-3 rapidly stimulated phosphorylation of Tyro3, peaking at 10 min and decreasing thereafter
(Figure 2). Significant Tyro3 activation was observed by Gal-3 from 0.1 µM concentration, with maximal
activation occurring at 0.2 µM in both cell lines. As we used GAPDH as a loading control in the blots,
we verified that the levels of total kinases did not change over the time periods of the experiments
(Figure S1). In contrast to its effect on Tyro3, Gal-3 had no effect on Axl phosphorylation levels in
SCC-25 cells over the 15 min time period of study (Figure S2).Biomolecules 2020, 10, x 6 of 17 
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ANOVA with Tukey’s multiple comparison post-hoc analysis; **** p< 0.0001, *** p < 0.001, ** p < 0.01, 
* p < 0.05 versus control (time 0 or untreated) (n = 3 separate experiments). 
Next, the TAM receptor-activating effects of Gal-3 were directly compared against those of the 
two canonical TAM ligands, Gas6 and ProS1, using Gal-3 at 0.2 μM concentration and 9 min 
stimulation time as optimal experimental conditions from the previous observations. All three 
exogenous proteins significantly stimulated phosphorylation of Tyro3 in both SCC-25 and MGH-U3 
cell lines (Figure 3). ProS1 was the strongest ligand, stimulating Tyro3 roughly twice as much as 
both Gas6 and Gal-3. Nevertheless, Gal-3 stimulated Tyro3 to at least the same extent as Gas6. In 
contrast, Axl in SCC-25 cells was stimulated only by Gas6 (Figure S3). Therefore, these experiments 
show that Gal-3 selectively stimulates Tyro3 but not Axl. 
Figure 2. Effect of Gal-3 stimulation on phosphorylation of TAM receptors. (A) Representative Western
blots showing phosphorylated Tyro3 (pTyro3) protein in SCC-25 (A) and MGH-U3 (B) cells stimulated
by Gal-3 (0.2 µM) in time-course (left) and dose response (right) experiments (9 min stimulation).
Accompanying graphs show protein quantification by densitometric analysis of bands. Data are the
mean ± SEM protein expression normalised against GAPDH as loading control protein; ANOVA with
Tukey’s multiple comparison post-hoc analysis; **** p< 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 versus
control (time 0 or untreated) (n = 3 separate experiments).
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Next, the TAM receptor-activating effects of Gal-3 were directly compared against those of the two
canonical TAM ligands, Gas6 and ProS1, using Gal-3 at 0.2 µM concentration and 9 min stimulation
time as optimal experimental conditions from the previous observations. All three exogenous proteins
significantly stimulated phosphorylation of Tyro3 in both SCC-25 and MGH-U3 cell lines (Figure 3).
ProS1 was the strongest ligand, stimulating Tyro3 roughly twice as much as both Gas6 and Gal-3.
Nevertheless, Gal-3 stimulated Tyro3 to at least the same extent as Gas6. In contrast, Axl in SCC-25
cells was stimulated only by Gas6 (Figure S3). Therefore, these experiments show that Gal-3 selectively
stimulates Tyro3 but not Axl.Bio olecules 2020, 10, x 7 of 17 
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3.3. Gal-3 Activates Both Erk and Akt Signalling in Human Cancer Cells
As with the receptors, Gal-3 was also compared against the two canonical TAM ligands for their
capacity to stimulate intracellular Erk and Akt signalling kinases in SCC-25 cells. Ligands were added
in experiments alone or in combination. All three proteins rapidly stimulated Erk1/2 phosphorylation
by two-fold (Figure 4). However, Akt phosphorylation was stimulated by Gas6 and Gal-3 but not by
ProS1, the latter observation confirming what we have shown before in these cells [6].
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indicating that Gal-3 could activate receptors/pathways also beyond Tyro3, to which ProS1 and 
Gas6 were necessarily restricted. In addition, all three proteins significantly protected cells from 
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Figure 4. Representative Western blots showing levels of phosphorylated Akt (pAkt) and Erk (pErk)
proteins in SCC-25 cells, following addition of Gas6 (5.7 nM), ProS1 (7.5 nM) and Gal-3 (0.2 µM),
either alone or in combination, as indicated by the labelling. Densitometric quantification is shown
below. Data are the mean ± SEM protein expression normalised against the loading control protein
GAPDH (n = 3 experiments). ANOVA with Tukey’s multiple comparison post-hoc analysis. * p < 0.05,
** p < 0.01, *** p < 0.001 and ns, not significant vs. the control or between treatments indicate by lines.
3.4. Gal-3 Protects Cells from Acute Apoptosis by Staurosporine
Flow cytometry revealed that Gal-3 significantly protected cancer cells from acute apoptosis
induced by staurosporin (Figure 5). In both SCC-25 and MGH-U3 cell lines, the presence of Gal-3
together with rosporine significantly reduced the percentage of cells undergoing apoptosis
as c mpared o treatment with staurosporine alone (Figure 5). Moreover, MGH-U3 cells,
the anti- popt tic effect of Gal-3 was significa tly stronger than that of the two canonic l TAM
ligands, indicating that Gal-3 could activate receptors/pathways also beyond Tyro3, to which ProS1
and Gas6 were necessarily restricted. In addition, all three proteins significantly protected cells from
acute apoptosis by staurosporine also in an MTS assay (Figure S4).
As an alternative means by which to induce apoptosis, cells were subjected to long-term serum
starvation to determine the effect of Gal-3 on cell viability under those conditions by MTS assay. Under
long-term serum starvation conditions, only Gas6 out of the three proteins conferred a significant
positive survival effect on cells when used as sole agent (Figure 6). Nevertheless, there was a trend
towards significance with Gal-3 when used as sole agent, in terms of counteracting the serum
starvation-induced apoptosis. Furthermore, a significant protection from apoptosis was achieved
when Gal-3 was combined with ProS1, which also did not have a significant effect alone, indicating an
additive effect.
3.5. Comparative Effects of Gal-3 vs. TAM Ligands on Genes Regulating Cell Cycle Progression and Apoptosis
To build on the observations made on Gal-3 and TAM ligand activation of Erk and Akt signalling
in human cancer cells, we analysed the expression of a set of genes well known to regulate apoptosis
or cell progression following stimulation with Gal-3 and the two TAM ligands. SCC-25 and MGH-U3
cells were treated with staurosporine for 20 h to induce apoptosis, in the absence or presence of each
individual protein, followed by qRT-PCR analysis of each gene. In both cell lines, staurosporine alone
caused a strong reprogramming of gene expression in a pro-apoptotic direction, upregulating the
pro-apoptotic genes APAF-1 and BAX whilst downregulating the anti-apoptotic gene BCLXL (Figure 7).
Staurosporine also affected genes leading to cell cycle arrest, including downregulating CCND1 and
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upregulating CDKN2A gene expression. In both cell lines, co-treatment of staurosporine with each of
the three proteins reversed the effect of staurosporine alone, with variations amongst the proteins.Biomolecules 2020, 10, x 9 of 17 
 
Figure 5. Effect of Gal-3 on cancer cells undergoing apoptosis and role of the TAM receptor 
expression profile in mediating these effects. Flow cytometry results showing percentage of SCC-25 
(A) and MGH-U3 (B) cells undergoing apoptosis (Annexin V-FITC/PI double-stained) by 20 h 
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mean ± SEM and underwent ANOVA with Tukey’s multiple comparison post-hoc analysis; ****p < 
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Figure 5. Effect of Gal-3 on cancer cells undergoing apoptosis and role of th TAM receptor xpression
profile in mediating these effects. Flow cytometry results showing percentage of SCC-25 (A) and
MGH-U3 (B) cells undergoing apoptosis (Annexin V-FITC/PI double-stained) y 20 h incu ation with
staurosporine (STS; 0.1 µM), with co-incubation with Gal-3 and TAM ligands added 1 h previously.
Graphs show proportions (%) of healthy, apoptotic and necrotic cells. Data are the mean ± SEM and
underwent ANOVA with Tukey’s multiple comparison post-hoc analysis; **** p < 0.0001, *** p < 0.001,
** p < 0.01 versus the same category of cells in the STS alone treated group (n = 3 experiments).
(#) indicates the comparisons between Gal-3 cell fraction versus the same category of cells in both Gas6
and ProS1 treatment groups; p < 0.05.
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Figure 7. Quantitative RT-PCR analysis of effects of Gal-3 and TAM ligands on the expression of
genes regulating apoptosis (BAX, BCLXL, APAF-1) and cell cy l progression (C ND1, CDKN2A) in
SCC-25 (A) and MGH-U3 (B) cancer cells. Cells were treated for 20 h with staurosporine (STS; 0.1 µM),
with co-incubation with Gas6 (5.7 nM), ProS1 (7.5 nM) or Gal-3 (0.2 µM) added 2 h previously. Relative
gene expression is represented as fold change, (2−∆∆Ct) is the normalised gene expression (2-∆Ct) in the
treated samples divided by the normalised gene expression (2−∆Ct) in the control sample (untreated;
UT). Relative gene expression in each sample was normalised against the housekeeping gene GAPDH.
Data are the mean ± SEM and underwent ANOVA with Tukey’s multiple comparison post-hoc analysis;
**** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05 versus STS-treated sample (n = 3 experiments).
3.6. Galectin-3 Stimulates Cancer Cell Migration During Axl Blockade
The influence of Gal-3 on the linear migration of SCC-25 cancer cells was easured by “scratch
wound” assay combined with time lapse microscopy. Platelet-derived growth factor (PDGF; 10 nM)
was used as a positive control for cell migration. Exogenous Gal-3 did not affect cell migration rate
alone; however, when Gal-3 was co-incubated with cells together with the Axl inhibitor BGB324, which
on its own markedly reduced the rate of cell migration, Gal-3 significantly reversed the reduction in
migration due to Axl blockade (Figure 8). This indicates that Gal-3 is able to stimulate cell migration
via pathways independent of Axl, which may include Tyro3.
Biomolecules 2020, 10, 1035 11 of 15
Biomolecules 2020, 10, x 13 of 17 
reduction in migration due to Axl blockade (Figure 8). This indicates that Gal-3 is able to stimulate 
cell migration via pathways independent of Axl, which may include Tyro3.  
 
Figure 8. Effect of Gal-3 on cell migration. Cell migration rate of SCC-25 cells in scratch wound 
assay, expressed as a percentage vs. the control (untreated). Cells were treated with PDGF (10 nM) 
as a positive control, Gal-3 (0.2 μM), Axl inhibitor BGB324 (BGB; 10 μM) and a combination of both 
Gal-3 and BGB324. The averages of gap distance at 0 and 21 h and the gap closure rate were 
calculated for each set of treatments. Data are the mean ± SEM and underwent ANOVA with 
Tukey’s multiple comparison post-hoc analysis; **** p < 0.0001, ** p < 0.01 for comparisons indicated 
by lines (n = 4 experiments). 
4. Discussion 
The homologous vitamin K-dependent proteins Gas6 and ProS1 were first identified as ligands 
for the TAM RTKs in the mid-1990s [3]. Since then, a long period of time elapsed before evidence 
was presented for the existence of novel TAM ligands. A study of mediators of phagocytosis 
identified the proteins Gal-3 and Tubby to bind to and activate MerTK, and TULP-1, which bound 
all three TAMs [17]. MerTK binding by Gal-3 was suggested to occur through the latter’s C-terminal 
carbohydrate recognition domain (CRD), which may harbour a MerTK-binding motif found in the 
two LG domains in ProS1 and Gas6, or the MPD motif of Tubby and Tulp-1 [7]. The presence of 
such a motif in Gal-3 therefore also laid open the possibility of significant affinity for TAMs other 
than MerTK. Moreover, given Gal-3′s high affinity for glycans and the likely presence of N-linked 
glycosylation on the surface of all three TAMs, there was also a possibility of Gal-3 binding to 
TAMs as a canonical lectin, and thus in a manner distinct from the two vitamin K-dependent TAM 
ligands. 
In the present study, Gal-3 stimulated phosphorylation of Tyro3 in both time- and 
concentration-dependent manners in both SCC-25 and MGH-U3 cancer cell lines. This was 
mirrored by Gal-3 stimulation of Erk kinase phosphorylation, and hence there was a similarity with 
the ProS1-Tyro3 axis which we have previously uncovered [6]. The use of these two cell lines with 
distinct natural TAM expression profiles (specifically differing in Axl expression) enabled us to 
demonstrate that Gal-3 has agonistic activity selectively via Tyro3 but not via Axl. A high basal 
level of Axl activation in these cells could indicate that Gal-3 may have been able to stimulate Axl if 
Axl expression was lower; however, these cells are still responsive to Gas6 and therefore any 
Figure 8. Effect of Gal-3 on cell migration. Cell migration rate of SCC-25 cells in scratch wound assay,
expressed as a percentage vs. the control (untreated). Cells were treated with PDGF (10 nM) as a
positive control, Gal-3 (0.2 µM), Axl inhibitor BGB324 (BG ; 10 µM) a combinati n f both Gal-3
and BGB324. The averages of gap distance at 0 and 21 h and the gap closure rate were calculated
for each set of treatments. Data are the mean ± SEM and underwent ANOVA with Tukey’s multiple
comparison post-hoc analysis; **** p < 0.0001, ** p < 0.01 for comparisons indicated by lines (n = 4
experiments).
4. Discussion
The homologous vitamin K-dependent proteins Gas6 and ProS1 were first identified as ligands
for the TAM RTKs in the mid-1990s [3]. Since then, a long period of time elapsed before evidence
was presen ed for the existence of novel TAM li ands. A study of mediators of phagocytosis
identified the proteins Gal-3 and Tubby to bind to and activate MerTK, and TULP-1, which bound
all three TAMs [17]. MerTK binding by Gal-3 was suggested to occur through the latter’s C-terminal
carbohydrate recognition domain (CRD), which may harbour a MerTK-binding motif found in the two
LG domains in Pr S1 and Gas6, or the MPD motif of Tubby and Tulp-1 [7]. The presence of such a
motif in Gal-3 therefore also laid open the possibility of significant affinity for TAMs other than MerTK.
Moreover, given Gal-3′s high affinity for glycans and the likely presence of N-linked glycosylation
on the surface of all three TAMs, there was also a possibility of Gal-3 binding to TAMs as a canonical
lectin, and thus in a manner disti ct f om th two vitamin K-dependent TAM ligands.
In the present study, Gal-3 stimulated phosphorylation of Tyro3 in both time- and concentration-
dependent manners in both SCC-25 and MGH-U3 cancer cell lines. This was mirrored by Gal-3
stimulation of Erk kinase phosphorylation, and hence there was a similarity with the ProS1-Tyro3 axis
which we have previously uncovered [6]. The u e of these two c ll line with distinct natural TAM
expression profiles (specifically differing in Axl expression) enabled us to demonstrate that Gal-3 has
agonistic activity selectively via Tyro3 but not via Axl. A high basal level of Axl activation in these cells
could indicate that Gal-3 may have been able to stimulate Axl if Axl expression was lower; however,
these cells are still responsive to Gas6 and therefore any agonistic potential of Gal-3 against Axl is
likely to be low, alongside glycosylation differences between the TAM receptors, as discussed later.
Nevertheless, these data represent the first observation that Gal-3 is an agonist for Tyro3 receptor,
and validates the original report by Caberoy et al. [7] which identified Gal-3 as a ligand for MerTK.
The concentrations of Gal-3 observed to be active here indicate that, as with growth factors, it is likely
to be the local concentrations of the protein surrounding the cells within a tumour that determine the
efficacy of the protein.
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The TAMs are known to have N-linked glycosylation sites on their surface that could potentially
be recognition sites for lectins such as Gal-3. All three TAMs possess multiple asparagine (N) residues
within their amino acid sequences (Figure S5) [18]. However, it is clear that Tyro3 and MerTK have
more potential glycosylation sites than Axl, as well as there being a higher incidence of similarities
in terms of the locations of glycosylation sites in both MerTK and Tyro3 but not in Axl, for example
N63 and N293 in Tyro3 and N114 and N354 in MerTK. Therefore, the presence of certain homologous
asparagine residues in Tyro3 and MerTK, but their absence in Axl, may explain our observation that
Gal-3 stimulated Tyro3 (and MerTK as observed by Caberoy et al. [7]) but failed to stimulate Axl. Thus,
one or more of these potential N-linked glycosylation sites exclusive to Tyro3 and MerTK could form
an interaction interface with Gal-3.
In addition to receptor selectivity, Gal-3 was observed to activate both intracellular Erk and
Akt signalling in SCC-25 cancer cells. This observation distinguishes Gal-3 from ProS1 due to the
additional capacity of Gal-3 to activate Akt (which ProS1 lacks), whereas a distinction from Gas6 lies in
the observation that Gal-3 failed to stimulate Axl receptor. Therefore, these results may suggest that
Gal-3 is connected to the Tyro3-Erk signalling axis as well as, additionally, downstream Akt signalling,
although not via Axl but possibly through one or more other RTKs (Figure 9). Our findings here on
Tyro3 add to and concur with those on other RTKs, via which Gal-3 has been shown to activate Erk
and Akt signalling. This therefore suggests a commonality in the signalling mechanism by which
Gal-3 exerts its effects on cancer cells via RTKs. In addition, our findings here reveal similarities and
differences between Gal-3 and the two canonical ligands. Gal-3 also protected cells from apoptosis
induced by staurosporine (short term) but not after serum starvation (long term), which likens it
to ProS1 but not Gas6, which had the most powerful and durable cell survival effect. Therefore,
Gal-3 may act via Tyro3 in cells in the same manner as ProS1, which accounts for its more limited
cell survival effects as opposed to Gas6, which activates Axl to exert a more pronounced cell survival
function [18]. Nevertheless, the Gal-3 effect approached statistical significance in terms of counteracting
the serum starvation-induced apoptosis and, moreover, both Gal-3 and ProS1 together were able to
stimulate survival-signalling pathways to a sufficient degree through an additive effect. Furthermore,
gene expression analysis by RT-qPCR showed that Gal-3 counteracted the apoptosis-inducing and cell
cycle arresting effects of staurosporine in cells, therefore emulating the TAM ligands as activators of
cell survival and proliferative signalling.
Further in keeping with its activation of pro-tumorigenic signalling pathways in cancer cells,
Gal-3 was also able to stimulate human cancer cell migration. Although Gal-3 was a weak stimulator
of migration as sole agent, this observation was likely due to an already high basal rate of migration
in these cells that masked the Gal-3 ligand potential. However, Gal-3 had a clearer and pronounced
stimulatory effect when the component of cell migration that was mediated through Axl signalling was
blocked in the presence of the small molecule inhibitor Axl BGB324. It could alternatively be stated that
Gal-3 significantly hindered the suppressive effect of Axl blockade on cell migration. This observation
therefore indicates that Gal-3 signals towards cell migration, at least in part, independently of Axl.
However, as this signalling is unlikely to occur via Tyro3, the specific receptor-mediated pathway for
this remains to be determined.
Therefore, in this study we have identified Gal-3 as a novel selective agonist/ligand for Tyro3
RTK, which highlights a similarity with the other TAM, MerTK, but a difference with Axl. However,
it remains to be observed whether Gal-3 acts as a ligand for Tyro3 through direct physical binding of the
receptor; this can be determined through e.g. a receptor binding assay. Furthermore, it is also currently
unknown whether Gal-3 interacts with TAM receptors through its lectin properties, i.e. with a glycosyl
chain on the RTK, or else via another as yet unidentified interaction interface. Overall, the effects of
Gal-3 on e.g. cancer cell survival and migration are likely due to a combination of effects via several
cell surface receptors. As Gal-3 is considered as a biomarker for many cancers, often showing increased
expression, knowledge on the molecular mechanisms by which it affects cancer cells, e.g. through
Tyro3 activation as shown here, it can offer a novel avenue for cancer therapeutics and/or diagnostics.
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For example, Gal-3′s ability to mediate the clearance of apoptotic cells via MerTK implicates it as a
role player in immune resistance and immunosuppression, contributing to conditions such as cancer
and autoimmune diseases [19]. Additionally, Gal-3 expression has been used to determine treatment
responsiveness, as, for example, negative/low levels of Gal-3 indicate an early and durable response
to immunotherapy in lung cancer [20]. Furthermore, other than cancer, Gal-3 shows promise as a
biomarker for many other diseases including hepatitis [21], cardiovascular diseases [22], chronic kidney
disease and Alzheimer’s disease [23]. In some of these diseases the TAM receptors may also feature,
thus potentially indicating involvement of a Gal-3/TAM signalling axis in the underlying mechanisms.
Further work is required to elucidate the precise molecular mechanisms surrounding Gal-3-TAM
receptor interaction and its downstream functional consequences in different pathologies.Biomolecules 2020, 10, x 15 of 17 
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